Vaccine (Recombinant protein vaccine) · Immune activation, directed at SARS-CoV-2 spike protein and Influenza virus hemagglutinin · developed by Novavax
qNIV vaccine is a combination vaccine administered as intramuscular injections on Days 0 and 70. It is studied for prevention of COVID-19 and influenza.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05519839 | Phase 2 | COVID-19 | Completed | NVAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19Influenza
Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.
See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVAX catalysts and pipeline →